Literature DB >> 11023517

Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils.

C Hess1, S Sadallah, J A Schifferli.   

Abstract

Antibodies against myeloperoxidase (MPO) and proteinase 3 (PR3) are the predominant autoantibodies present in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Their binding to the corresponding antigen on the surface of polymorphonuclear neutrophils (PMNs) is believed to trigger the disease process. Cytokines released during an inflammatory reaction are thought to prime resting PMNs, making them responsive to autoantibodies. In the present study we found that MPO but not PR3 could be detected on the cell surface of unstimulated PMNs after incubation with the supernatants of activated autologous PMNs. MPO was shown to be acquired from these supernatants, because PMNs did not express MPO when the supernatants were specifically MPO-depleted. In addition, purified soluble MPO bound to unstimulated PMNs. Unstimulated PMNs that had passively acquired MPO released oxygen radicals when incubated with monoclonal antibody anti-MPO or the immunoglobulin G fraction of a patient with MPO-ANCA. The data presented here suggest that, in ANCA-associated vasculitis, soluble MPO released by activated PMNs may bind to unstimulated PMNs, thereby making them reactive to anti-MPO antibodies. This mechanism of dispersing PMN activation would be specific for MPO-ANCA and may explain differences in the pathologic and clinical expression of MPO-ANCA versus PR3-ANCA vasculitis. (Blood. 2000;96:2822-2827)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023517

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

Review 2.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

Authors:  Maria C Cid; Marta Segarra; Ana García-Martínez; Jose Hernández-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 3.  Ectosomes as modulators of inflammation and immunity.

Authors:  S Sadallah; C Eken; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

Review 4.  Ectosomes as immunomodulators.

Authors:  Salima Sadallah; Ceylan Eken; Jürg A Schifferli
Journal:  Semin Immunopathol       Date:  2010-12-07       Impact factor: 9.623

Review 5.  Cell-cell communication via extracellular membrane vesicles and its role in the immune response.

Authors:  Inkyu Hwang
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

Review 6.  How anti-neutrophil cytoplasmic autoantibodies activate neutrophils.

Authors:  R Kettritz
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 7.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

8.  Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

Authors:  Dennis Huugen; Hong Xiao; Anita van Esch; Ronald J Falk; Carine J Peutz-Kootstra; Wim A Buurman; Jan Willem Cohen Tervaert; J Charles Jennette; Peter Heeringa
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

Review 9.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

10.  Increased plasma myeloperoxidase levels in systemic lupus erythematosus.

Authors:  Rosa Weiss Telles; Gilda Aparecida Ferreira; Neusa Pereira da Silva; Emilia Inoue Sato
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.